The Speed Bump Test: Finding the "Win-Win" in a Stage IV Diagnosis

For Betsy Jones, life has always been about the quiet, steady joys: a 28-year marriage to her husband, Mike; navigating the empty-nest transition with her two sons; and enjoying the methodical challenge of a good jigsaw puzzle. But in April 2019, Betsy's life became a puzzle of a very different kind.

It started with a strange feeling of fullness after eating only small amounts of food. Within a week, the Florida native turned Texan found herself sitting in an oncologist's office, facing a staggering diagnosis: Stage IV metastatic breast cancer.

"I thought, 'Is this a joke?’ I didn't even know how many stages there were. It was all brand new,” Betsy said.

The Path Less Traveled

Betsy describes herself as an “odd duck” in the clinical world. Despite her diagnosis, doctors never found a primary tumor in her breasts. Instead, what she calls “rogue cells” had migrated directly to her bones.

For six years, she responded remarkably well to targeted hormone therapy at UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center, exceeding the typical treatment window many patients experience.

In May 2025, however, the treatment stopped working. The cancer had spread to her peritoneum, causing painful fluid buildup and frequent medical procedures.

"I was going in for paracentesis every two weeks,” Betsy said. “They were drawing off nearly four liters. Imagine two large soda bottles coming out of you. It was miserable."

The "Win-Win" of Research

For Betsy, enrolling in a clinical trial was not an act of desperation. Instead, she viewed it as a strategic win-win. Her oncologist had reassured her that standard treatment options would still be fully available down the road. If the trial drug was unsuccessful or caused tough side effects, she could voluntarily withdraw at any time, leaving standard hormone therapies safely on the table as a backup. If it worked, it offered the possibility of a more precise approach, targeting the specific PIK3 mutation driving her cancer's progression.

However, this precision required a significant adjustment to her routine; unlike her previous regimen, which gave her body a one-week break to recover after three weeks of use, this new trial drug demanded a constant, twice-daily commitment with no breaks. But it proved to be worth it, she said.

"I used to have to brace myself every time we went over a speed bump because of the spots on my spine. It hurt so much,” she said. Those spots were the result of rogue cancer cells that had migrated to her bones, pelvis, spine, and femur. However, after participating in the trial since July 2025, she experienced a remarkable shift. "Last weekend, my friend hit a bump while we were talking, and I realized I hadn't braced myself," she said. “I wasn't even paying attention. It didn't hurt." Beyond the physical relief, the clinical trial provided her with an exceptional level of medical care. While she felt well taken care of during her initial treatments, transferring to the trial took her experience from “great to awesome.”